Table 1. Comparison of the demographics and clinicopathological characteristics according to BMI subgroup.
| Parameters | BMI quartiles | ||||
|---|---|---|---|---|---|
| 0%-25% (<21.7 kg/m2) |
25%-50% (21.7-23.7 kg/m2) |
50%-75% (23.8-25.7 kg/m2) |
75%-100% (≥25.8 kg/m2) |
P value | |
| No. of patients | 110 | 110 | 110 | 110 | |
| Age (yr, mean ± SD) | 68.0 ± 11.4 | 65.3 ± 10.8 | 65.6 ± 10.0 | 65.5 ± 10.3 | 0.182* |
| ASA-PS score | 0.153† | ||||
| 1 | 31 (25.9) | 29 (28.7) | 32 (31.4) | 26 (24.5) | |
| 2 | 59 (56.2) | 67 (66.3) | 65 (63.7) | 69 (65.1) | |
| 3 | 15 (14.3) | 5 (5.0) | 5 (4.9) | 11 (10.4) | |
| Smoking history (%) | 41 (37.3) | 25 (22.7) | 34 (30.9) | 25 (22.7) | 0.066† |
| Gender (%) | 0.666† | ||||
| Male | 80 (72.7) | 78 (70.9) | 75 (68.2) | 72 (65.5) | |
| Female | 30 (27.3) | 32 (29.1) | 35 (31.8) | 38 (34.5) | |
| Previous or concomitant NMIBC (%) | 18 (16.4) | 19 (17.3) | 30 (27.3) | 21 (19.1) | 0.164† |
| Tumor location (%) | 0.456† | ||||
| Renal pelvis | 46 (41.8) | 38 (34.5) | 41 (37.3) | 34 (30.9) | |
| Ureter | 49 (44.5) | 55 (50.0) | 51 (46.4) | 64 (58.2) | |
| Both | 15 (13.6) | 17 (15.5) | 18 (16.4) | 12 (10.9) | |
| Pathologic T stage (%) | 0.578† | ||||
| Tis | 1 (0.9) | 2 (1.8) | 2 (1.8) | 3 (2.7) | |
| Ta | 3 (2.7) | 6 (5.5) | 5 (4.5) | 9 (8.2) | |
| T1 | 34 (30.9) | 34 (30.9) | 32 (29.1) | 35 (31.8) | |
| T2 | 29 (26.4) | 21 (19.1) | 29 (26.4) | 32 (29.1) | |
| T3 | 40 (36.4) | 46 (41.8) | 41 (37.3) | 28 (25.5) | |
| T4 | 3 (2.7) | 1 (0.9) | 1 (0.9) | 3 (2.7) | |
| Pathologic N stage (%) | 0.486† | ||||
| Nx | 46 (41.8) | 55 (50.0) | 50 (45.5) | 61 (55.5) | |
| N0 | 59 (53.6) | 49 (44.5) | 54 (49.1) | 46 (41.8) | |
| N1-2 | 5 (4.5) | 6 (5.5) | 6 (5.5) | 3 (2.7) | |
| Tumor grade (%) | 0.463† | ||||
| Low | 23 (20.9) | 25 (22.7) | 30 (27.3) | 32 (29.1) | |
| High | 87 (79.1) | 85 (77.3) | 80 (72.7) | 78 (70.9) | |
| Multiplicity (%) | 30 (27.3) | 32 (29.1) | 27 (24.5) | 22 (20.0) | 0.434† |
| Concomitant CIS (%) | 4 (4.6) | 8 (8.4) | 7 (7.6) | 11 (11.5) | 0.403† |
| Lymphovascular invasion (%) | 19 (17.3) | 20 (18.2) | 19 (17.3) | 18 (16.4) | 0.988† |
| Positive surgical margin (%) | 8 (7.3) | 8 (7.3) | 3 (1.8) | 5 (4.5) | 0.209† |
| Adjuvant chemotherapy | 23 (20.9) | 21 (19.1) | 22 (20.0) | 12 (10.9) | 0.187† |
P value was based on the *ANOVA and †Fisher exact test. BMI, body mass index; SD, standard deviation; BC, bladder cancer; ASA-PS, American Society of Anesthesiologists Physical Status; NMIBC, non-muscle invasive bladder cancer; CIS, carcinoma in situ.